Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial

Vela, Jonathan; Dreyer, Lene; Petersen, Kristian Kjær; Arendt-Nielsen, Lars; Duch, Kirsten; Kristensen, Salome

doi:10.1097/j.pain.0000000000002466

Cited by 61 publications

(48 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…2B). The to date single RCTs with CBD vs placebo [153] and dronabinol vs active drug [69] reported no effect.…”

Section: Primary Outcomes Chronic Painmentioning

confidence: 99%

“…Symptoms of depression caused by diverse medical conditions were evaluated with dronabinol in seven RCTs versus placebo [12,23,45,75,92,102,117] and in one study versus prochlorperazine [86]; with nabilone, three studies comparing placebo [118,125,151] and two comparing an active drug [121,123] were carried out; placebo was compared with CBD in 6 RCTs [15,19,22,24,153,154] and with nabiximols in 7 RCTs [48,49,53,[61][62][63][64].…”

Section: Depressionmentioning

confidence: 99%

“…*compared to placebo and one cross-over[100] with diazepam; with nabilone, 6 trials[118,125,143,149,152,162] used placebo and two trials[120,123] used active comparators; and eight CBD[13,15,19,22,153,[157][158][159] and 23 nabiximols[10, 33-35, 37, 38, 40, 41, 43, 44, 46-52, 57, 58, 61-63] used placebo. The…”

mentioning

confidence: 99%

See 2 more Smart Citations

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

Bilbao

Spanagel

2022

BMC Med

View full text Add to dashboard Cite

Background Medical cannabinoids differ in their pharmacology and may have different treatment effects. We aimed to conduct a pharmacology-based systematic review (SR) and meta-analyses of medical cannabinoids for efficacy, retention and adverse events. Methods We systematically reviewed (registered at PROSPERO: CRD42021229932) eight databases for randomized controlled trials (RCTs) of dronabinol, nabilone, cannabidiol and nabiximols for chronic pain, spasticity, nausea /vomiting, appetite, ALS, irritable bowel syndrome, MS, Chorea Huntington, epilepsy, dystonia, Parkinsonism, glaucoma, ADHD, anorexia nervosa, anxiety, dementia, depression, schizophrenia, PTSD, sleeping disorders, SUD and Tourette. Main outcomes and measures included patient-relevant/disease-specific outcomes, retention and adverse events. Data were calculated as standardized mean difference (SMD) and ORs with confidence intervals (CI) via random effects. Evidence quality was assessed by the Cochrane Risk of Bias and GRADE tools. Results In total, 152 RCTs (12,123 participants) were analysed according to the type of the cannabinoid, outcome and comparator used, resulting in 84 comparisons. Significant therapeutic effects of medical cannabinoids show a large variability in the grade of evidence that depends on the type of cannabinoid. CBD has a significant therapeutic effect for epilepsy (SMD − 0.5[CI − 0.62, − 0.38] high grade) and Parkinsonism (− 0.41[CI − 0.75, − 0.08] moderate grade). There is moderate evidence for dronabinol for chronic pain (− 0.31[CI − 0.46, − 0.15]), appetite (− 0.51[CI − 0.87, − 0.15]) and Tourette (− 1.01[CI − 1.58, − 0.44]) and moderate evidence for nabiximols on chronic pain (− 0.25[− 0.37, − 0.14]), spasticity (− 0.36[CI − 0.54, − 0.19]), sleep (− 0.24[CI − 0.35, − 0.14]) and SUDs (− 0.48[CI − 0.92, − 0.04]). All other significant therapeutic effects have either low, very low, or even no grade of evidence. Cannabinoids produce different adverse events, and there is low to moderate grade of evidence for this conclusion depending on the type of cannabinoid. Conclusions Cannabinoids are effective therapeutics for several medical indications if their specific pharmacological properties are considered. We suggest that future systematic studies in the cannabinoid field should be based upon their specific pharmacology.

show abstract

“…2B). The to date single RCTs with CBD vs placebo [153] and dronabinol vs active drug [69] reported no effect.…”

Section: Primary Outcomes Chronic Painmentioning

confidence: 99%

Section: Depressionmentioning

confidence: 99%

See 1 more Smart Citation

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

Bilbao

Spanagel

2022

BMC Med

View full text Add to dashboard Cite

show abstract

“…We followed the methods guidance in the AHRQ Methods Guide, 17 and abstracted key information and conducted risk-of-bias assessments using the Cochrane Back Pain Group's version of the Cochrane guidance for randomized trials 18 and criteria developed by the U.S. Preventive Services Task Force 19 for observational studies for each included study. Our methods included categorizing studies based on the duration of followup as short-, intermediate-, and long-term.…”

Section: Methodsmentioning

confidence: 99%

Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Report 1

Singh¹,

VanderPluym²,

Hasan³

et al. 2022

View full text Add to dashboard Cite

This is the first surveillance report since the annual update of a living systematic review on cannabis and other plant-based treatments for chronic pain.The systematic review synthesizes evidence on the benefits and harms of plant-based compounds (PBCs), such as cannabinoids and kratom, used to treat chronic pain, and addresses concerns about severe adverse effects, abuse, misuse, dependence, and addiction.The purpose of this surveillance report is to describe new studies identified since the last search (April 2022) and provide a synthesis of the accumulated evidence. Surveillance update reports are planned on a quarterly basis, and the systematic review will be updated annually. The systematic review is available on the Agency for Healthcare Research and Quality (AHRQ) website (https://effectivehealthcare.ahrq.gov/products/plant-based-chronic-pain-treatment/livingreview). Table 1 provides a summary of the version history.

show abstract

“…Systemic CBD was also able to reduce the number of circulating neutrophils and inhibit inflammatory cytokine release in lipopolysaccharide-treated mice, providing further evidence for its anti-inflammatory action [ 24 ]. While the beneficial potential for CBD has been repeatedly shown in animal models of arthritis, human data are conflicting, suggesting the need for closer inspection [ 25 , 26 ].…”

Section: Introductionmentioning

confidence: 99%

Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis

McDougall

McKenna

2022

IJMS

View full text Add to dashboard Cite

Cannabis-based terpenes are believed to modulate physiological responses to disease and alter the efficacy of cannabinoids in the so-called “entourage effect”. The monoterpene myrcene can reduce nociception produced by noxious thermal and mechanical stimuli as well as reducing acute inflammation. The current study examined the role of myrcene and cannabidiol (CBD) in controlling chronic joint inflammation and pain. Chronic arthritis was induced in male Wistar rats by intra-articular injection of Freund’s complete adjuvant into the right knee. On days 7 and 21 after arthritis induction, joint pain (von Frey hair algesiometry), inflammation (intravital microscopy, laser speckle contrast analysis) and joint histopathology were assessed. Local application of myrcene (1 and 5 mg/kg s.c.) reduced joint pain and inflammation via a cannabinoid receptor mechanism. The combination of myrcene and CBD (200 μg) was not significantly different from myrcene alone. Repeated myrcene treatment had no effect on joint damage or inflammatory cytokine production. These data suggest that topical myrcene has the potential to reduce chronic arthritis pain and inflammation; however, it has no synergistic effect with CBD.

show abstract

Cannabidiol treatment in hand osteoarthritis and psoriatic arthritis: a randomized, double-blind, placebo-controlled trial

Abstract: Supplemental Digital Content is Available in the Text.No significant effects were found of 20 to 30 mg/day cannabidiol for 12 weeks on pain intensity in patients with hand osteoarthritis and psoriatic arthritis compared with placebo.

Cited by 61 publications

References 53 publications

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

Medical cannabinoids: a pharmacology-based systematic review and meta-analysis for all relevant medical indications

Systematic Review on Acute Treatments for Episodic Migraine: Surveillance Report 1

Anti-Inflammatory and Analgesic Properties of the Cannabis Terpene Myrcene in Rat Adjuvant Monoarthritis

Contact Info

Product

Resources

About